The Chief Medical Officer role in biotech is one of the most varied and demanding in the industry. As the biotech CMO community convenes at the CMO Summit 360° — the largest annual gathering of its kind — the conversations happening there reflect just how much the role has evolved and how differently it is defined across organisations of different sizes, stages and therapeutic focus.
What the biotech CMO role actually involves
The CMO role means fundamentally different things depending on the organisation. At an early-stage biotech with a single asset in Phase I, the CMO may be the primary clinical development strategist, regulatory relationship owner and scientific communicator to investors — a role that demands extraordinary breadth across a very small team. At a later-stage or commercial-stage biotech, the role expands to include leadership of a clinical organisation, oversight of medical affairs and active contribution to the commercial and market access strategy.
What these different manifestations share is the requirement to operate at the intersection of science, strategy and leadership — and to do so under the particular pressures of the biotech environment: limited resources, high stakes, significant investor scrutiny and the relentless pace of clinical development timelines.
The best biotech CMOs aren't just excellent clinicians or clinical development experts. They're leaders who can hold the scientific credibility of the organisation externally while building and motivating a clinical team internally — and who can do both simultaneously under pressure.
What good CMO hiring looks like
CMO searches in biotech are almost universally retained. The complexity of the role, the seniority of the appointment and the need for rigorous assessment of both scientific and leadership capability make contingency search inappropriate. A well-run CMO search typically takes four to six months from brief to start date — shorter timelines tend to produce compromises.
The assessment process needs to go beyond clinical development credentials. Boards and CEOs hiring a CMO should be testing for board-level communication capability, investor relations comfort, the ability to build and retain a clinical team and — critically — cultural fit with a leadership team that will be working in close proximity under pressure. Reference processes should be deep and multi-directional.
The European biotech CMO market
In Europe, the biotech CMO talent pool is concentrated around the major pharmaceutical and biotech hubs — Switzerland, the UK, Germany and the Nordics in particular. The most experienced CMO candidates in the European market have typically built careers that span multiple therapeutic areas and multiple geographies, and many have experience of both the European and US regulatory environments. That international profile is an asset but it also means that the competitive set for any European CMO search extends well beyond the immediate geography.